Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient. We could see the ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, ...

Medical professionals don’t pursue careers in healthcare out of a love of data entry, but it’s an inescapable daily reality for most, taking time away from focused care and consultations with patients ...

Technological advances are transforming medicine, but it may be making your physician less creative. Are technological advances making doctors lose the art of medicine? Of the many patients waiting to ...

CELZ-201-DDT is a proprietary allogeneic regenerative therapy designed to target the underlying pathology of DDD. Administered via ultrasound-guided injection, it offers a minimally invasive, ...

MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE ...

Growing older raises concerns about falling when nobody is around or getting urgent medical help with an unexpected medical ...

The strong performance was driven by the company’s mechanical thrombectomy portfolio, including AlphaVac and AngioVac, which grew 17.9%, while Auryon sales increased 17.9% and NanoKnife sales jumped ...

On the heels of the announcement of German bionics developer Ottobock SE KGaA's pending IPO and more than 20 med-tech IPOs completed to date in 2025, four other med-tech companies spanning three ...

MILAN — EssilorLuxottica’s acquisition spree shows no signs of slowing. The French-Italian eyewear juggernaut — which boasts a market cap of more than 131 billion euros — said Friday that it is ...

April data and first quarter earnings reports show remarkable resilience in med tech, even as other sectors continue to suffer in response to tariffs and changing regulations. Not that tariffs proved ...